Compare Bristol-Myers Squibb Co (BMY) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Alliant Energy Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.84 (market cap $129.94B), while Alliant Energy Corporation trades at $70.16 (market cap $17.78B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.3× Alliant Energy Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | LNT | |
|---|---|---|
Market Cap | $129.94B | $17.78B |
Sector | Health | Utilities |
52-Week High | $65.89 | $78.03 |
52-Week Low | $42.60 | $63.62 |
Enterprise Value | $163.92B | $29.88B |
Dividend Yield | 3.96% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Alliant Energy (LNT) trades at $70.01, up 2.64% today. The stock shows a bearish technical trend with support at $67-$68 and resistance at $69-$70. Fundamentally, the company reported strong Q2 2026 earnings of $0.65 per share, beating estimates, and maintains solid profitability with an 18.45% net income margin. Analyst consensus is a 'Buy' with a $77.67 price target, implying 11% upside. Recent news highlights institutional buying and dividend stability.
LNT offers a stable investment with consistent earnings growth and a reliable dividend, but faces risks from rising debt levels and regulatory pressures. The stock's current valuation at a P/E of 21.7 is reasonable for a utility, supporting a cautious bullish outlook amid technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
